September 7, 2019
Selvita doses first acute myleoid leukemia patient testing CDK8 inhibitor
Selvita has dosed the first patient in its Phase 1b study of CDK8 inhibitor, SEL120, which is being initially investigated in the treatment of patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS).